Curis, Inc. Augments Scientific Advisory Board With Leaders In Cancer Research And Development
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sept. 18, 2006--Curis, Inc., (NASDAQ: CRIS), a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, announced the addition of three new members to its Scientific Advisory Board: